Calcitriol Combined With Platinum-based Chemotherapy Suppresses Growth and Expression of Vascular Endothelial Growth Factor of SKOV-3 Ovarian Cancer Cells

2021 ◽  
Vol 41 (6) ◽  
pp. 2945-2952
Author(s):  
JU-HYUN KIM ◽  
WOOK HA PARK ◽  
DONG HOON SUH ◽  
KIDONG KIM ◽  
JAE HONG NO ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Cells ◽  
Ovarian Cancer Cells ◽  
Vascular Endothelial ◽  
Platinum Based Chemotherapy ◽  
Endothelial Growth Factor

scholarly journals Akt3 controls vascular endothelial growth factor secretion and angiogenesis in ovarian cancer cells

2011 ◽  
Vol 130 (3) ◽  
pp. 532-543 ◽  
Author(s):  
Tiera A. Liby ◽  
Perry Spyropoulos ◽  
Haley Buff Lindner ◽  
Juanita Eldridge ◽  
Craig Beeson ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Cells ◽  
Ovarian Cancer Cells ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor ◽  
Factor Secretion ◽  
Growth Factor Secretion

scholarly journals Positive Feedback between Vascular Endothelial Growth Factor-A and Autotaxin in Ovarian Cancer Cells

2008 ◽  
Vol 6 (3) ◽  
pp. 352-363 ◽  
Author(s):  
Malgorzata M. Ptaszynska ◽  
Michael L. Pendrak ◽  
Russell W. Bandle ◽  
Mary L. Stracke ◽  
David D. Roberts
Keyword(s):  
Ovarian Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Cells ◽  
Positive Feedback ◽  
Ovarian Cancer Cells ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

scholarly journals Vascular Endothelial Growth Factor Transcriptional Activation Is Mediated by Hypoxia-inducible Factor 1α, HDM2, and p70S6K1 in Response to Phosphatidylinositol 3-Kinase/AKT Signaling

2004 ◽  
Vol 279 (44) ◽  
pp. 45643-45651 ◽  
Author(s):  
Heath D. Skinner ◽  
Jenny Z. Zheng ◽  
Jing Fang ◽  
Faton Agani ◽  
Bing-Hua Jiang
Keyword(s):  
Ovarian Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Cells ◽  
Transcriptional Activation ◽  
Hypoxia Inducible Factor ◽  
Ovarian Cancer Cells ◽  
Vascular Endothelial ◽  
Vegf Expression ◽  
Endothelial Growth Factor

Vascular endothelial growth factor (VEGF) expression is elevated in ovarian and other cancer cells. However, the mechanism that causes the increase in VEGF expression still remains to be elucidated. In this study, we demonstrated that activation of PI3K signaling mediated VEGF protein expression at the transcriptional level through hypoxia-inducible factor 1α (HIF-1α) expression in human ovarian cancer cells. We found that inhibition of PI3K activity by LY294002 decreased VEGF transcriptional activation and that forced expression of AKT completely reversed the inhibitory effect. HDM2 and p70S6K1 are two downstream targets of AKT that mediate growth factor-induced VEGF transcriptional activation and HIF-1α expression. The inhibition of PI3K by LY294002 inhibited p70S6K1 and HDM2 activity in the cells. Forced expression of p70S6K1 or HDM2 reversed LY294002-inhibited VEGF transcriptional activation and HIF-1α expression. This study identifies a potential novel mechanism responsible for increased VEGF expression in ovarian cancer cells. It also indicates the important role of VEGF and HIF-1 in ovarian tumorigenesis and angiogenesis, which is mediated by the PI3K/AKT/HDM2 and AKT/p70S6K1 pathways in ovarian cancer cells.

scholarly journals Deregulation of angiopoietin-like 4 slows ovarian cancer progression through vascular endothelial growth factor receptor 2 phosphorylation

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yuxian Wu ◽  
Jinghai Gao ◽  
Xiaojun Liu
Keyword(s):  
Ovarian Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Cell Proliferation ◽  
Growth Factor ◽  
Cancer Cells ◽  
Ovarian Cancer Cell ◽  
Growth Factor Receptor ◽  
Ovarian Cancer Cells ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Abstract Background As a tissue-specific proangiogenic or antiangiogenic agent, angiopoietin-like 4 (ANGPTL4) has recently gained attention in many diseases, such as metabolic syndrome, cardiovascular disease and cancer. However, the roles of ANGPTL4 in angiogenesis and tumor growth in epithelial ovarian cancer, the most lethal gynecologic malignancy, remain unclear. Objective To identify a novel mechanism of ANGPTL4 inhibition in epithelial ovarian cancer. Methods Western blot, quantitative reverse transcription PCR, and immunofluorescence analyses were applied to evaluate ANGPTL4 expression in ovarian cancer cell lines. Cell proliferation, migration, and invasion were investigated through 5-ethynyl-2′-deoxyuridine (EdU) incorporation, CCK-8 and Transwell assays. The expression of epithelial-mesenchymal transition (EMT)-related proteins in ovarian cancer cells and tumor-bearing mice was evaluated. CD31 staining was used to identify tumor angiogenesis. Immunoprecipitation was performed to examine the regulatory relationship between ANGPTL4 and the vascular endothelial growth factor receptor 2 (VEGFR2)/vascular endothelial (VE)-cadherin/Src complex. VEGFR2 phosphorylation at Y949 and VE-cadherin expression were assessed by western blotting. Inactivation of VEGFR2 Y949 phosphorylation was achieved in a MISIIR-TAg VEGFR2Y949F/Y949F mouse model. Results Here, we demonstrated that ANGPTL4 was overexpressed in A2780 and CAOV3 ovarian cancer cells. In vitro assays indicated that inhibition of ANGPTL4 by lentiviral small interfering RNA does not alter ovarian cancer cell proliferation, migration, invasion, and EMT, while ANGPTL4 silencing exhibited significant inhibitory effects on tumor angiogenesis, growth, and metastasis in vivo. Immunoprecipitation analysis showed that suppression of ANGPTL4 was accompanied by dissociation of the VEGFR2/VE-cadherin/Src complex and phosphorylation of VEGFR2 Y949 in A2780 and CAOV3 ovarian tumors. Inactivation of VEGFR2 Y949 phosphorylation in MISIIR-TAg VEGFR2Y949F/Y949F mice abolished all tumor-suppressive effects of ANGPTL4 inhibition in spontaneous ovarian carcinoma. Conclusions Overall, our results indicate that ANGPLT4 silencing delays tumor progression in specific types of ovarian cancer and may be a potential target for individualized treatment of ovarian cancer.

Sign in / Sign up

Export Citation Format

Share Document